GR1006552B - Endoprostatic srping (stent) impregnated with rapamycin/sirolimus and shiga toxin acting against cancer of prostate and benign hyperplasias of the urologic tract - Google Patents
Endoprostatic srping (stent) impregnated with rapamycin/sirolimus and shiga toxin acting against cancer of prostate and benign hyperplasias of the urologic tractInfo
- Publication number
- GR1006552B GR1006552B GR20080100303A GR20080100303A GR1006552B GR 1006552 B GR1006552 B GR 1006552B GR 20080100303 A GR20080100303 A GR 20080100303A GR 20080100303 A GR20080100303 A GR 20080100303A GR 1006552 B GR1006552 B GR 1006552B
- Authority
- GR
- Greece
- Prior art keywords
- tissues
- rapamycin
- stent
- lymph
- prostate
- Prior art date
Links
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 4
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 108010079723 Shiga Toxin Proteins 0.000 title 1
- 206010020718 hyperplasia Diseases 0.000 title 1
- 201000001514 prostate carcinoma Diseases 0.000 title 1
- 210000002751 lymph Anatomy 0.000 abstract 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 3
- 229960002930 sirolimus Drugs 0.000 abstract 3
- 210000001519 tissue Anatomy 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000003053 toxin Substances 0.000 abstract 2
- 231100000765 toxin Toxicity 0.000 abstract 2
- 108700012359 toxins Proteins 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 210000004872 soft tissue Anatomy 0.000 abstract 1
- 101150081449 stxA gene Proteins 0.000 abstract 1
- 210000001550 testis Anatomy 0.000 abstract 1
- 210000000626 ureter Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/08—Coatings comprising two or more layers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Surgery (AREA)
- Medicinal Chemistry (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Abstract
Innovative use of the marketed Cypher (Cordis Company) and Shiga-stx/stxA toxins utilised before application of the stent described herein. Problem to be solved: impeding of the growth of hyperplasic benign or malignant tissues (soft tissues en general) due to the rapamycin acting on said tissues as well as on lymph cells (lymph tissues). It is disclosed a stent exhibiting known mechanical properties as well as immunostimulation activity when enriched with toxin. Possibility for depiction ofthe targeted hooking and thereby depiction of the tumour dynamic environment and pharmaceutical activity (drug carrier) in lymph tissues in general due to rapamycin utilization. Methodological stressing on all rapamycin utilizations (used alone, connected, or as a coating medium)on urologicorgans (kidney, prostate, ureter, lymphadens, testicle etc) as well as in lymph tissues in general (liquid-compact tissues) administrated in liquid form orally or directly applied on the tumour, alone or connected as referred to the description.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GR20080100303A GR1006552B (en) | 2008-04-24 | 2008-04-24 | Endoprostatic srping (stent) impregnated with rapamycin/sirolimus and shiga toxin acting against cancer of prostate and benign hyperplasias of the urologic tract |
PCT/GR2009/000027 WO2009130518A1 (en) | 2008-04-24 | 2009-04-23 | Intraprostatic stent coil-bar-pin infusion /injection method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GR20080100303A GR1006552B (en) | 2008-04-24 | 2008-04-24 | Endoprostatic srping (stent) impregnated with rapamycin/sirolimus and shiga toxin acting against cancer of prostate and benign hyperplasias of the urologic tract |
Publications (1)
Publication Number | Publication Date |
---|---|
GR1006552B true GR1006552B (en) | 2009-10-02 |
Family
ID=40791267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR20080100303A GR1006552B (en) | 2008-04-24 | 2008-04-24 | Endoprostatic srping (stent) impregnated with rapamycin/sirolimus and shiga toxin acting against cancer of prostate and benign hyperplasias of the urologic tract |
Country Status (2)
Country | Link |
---|---|
GR (1) | GR1006552B (en) |
WO (1) | WO2009130518A1 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2014DN10834A (en) * | 2001-09-17 | 2015-09-04 | Psivida Inc | |
US20050255230A1 (en) * | 2004-05-17 | 2005-11-17 | Clerc Claude O | Method of manufacturing a covered stent |
US20060067977A1 (en) * | 2004-09-28 | 2006-03-30 | Atrium Medical Corporation | Pre-dried drug delivery coating for use with a stent |
WO2006099470A2 (en) * | 2005-03-15 | 2006-09-21 | Surmodics, Inc. | Compliant polymeric coatings for insertable medical articles |
US20070162110A1 (en) * | 2006-01-06 | 2007-07-12 | Vipul Bhupendra Dave | Bioabsorbable drug delivery devices |
-
2008
- 2008-04-24 GR GR20080100303A patent/GR1006552B/en active IP Right Grant
-
2009
- 2009-04-23 WO PCT/GR2009/000027 patent/WO2009130518A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2009130518A1 (en) | 2009-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201809231T4 (en) | Combination therapy with hyaluronidase and a tumor-driven taxane. | |
CL2009001014A1 (en) | Superfast acting insulin composition comprising insulin and a hyaluronan degrading enzyme; closed loop system comprising the composition; method of preparing the composition; use of composition. | |
MX2010006991A (en) | Therapeutic cancer treatments. | |
MX347298B (en) | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages. | |
MX2015013244A (en) | Dissolvable gel-forming film for delivery of active agents. | |
RS53466B (en) | Use of amisulpride for treating post-operative nausea and vomiting | |
MX2011003557A (en) | Interface layer wound dressing. | |
DE602007010807D1 (en) | DEVICE FOR COMBINED TREATMENT | |
WO2009127882A3 (en) | A mobile wireless device with an embedded media player | |
PH12014500213A1 (en) | Poly (acrylate) polymers for in vivo nucleic acid delivery | |
NZ591719A (en) | Balloon catheter medical device coated with therapeutic agent and povidone-iodine | |
WO2011103146A3 (en) | A post foaming gel composition comprising an anti-irritation agent | |
BR112013006331A2 (en) | fulvestrant compositions and methods of use | |
WO2007128973A3 (en) | Interleukin 1-receptor antagonist composition to treat restenosis | |
ATE528013T1 (en) | VACCINE COMPOSITIONS | |
WO2011088178A3 (en) | Personal care composition comprising a hydrophobically modified cationic polysaccharide | |
DK2124640T3 (en) | Glucose isomerase for use in the treatment of fructose intolerance | |
WO2014121224A3 (en) | Biodegradable iron oxide nanoparticle gel | |
TN2011000250A1 (en) | Prophylactic/therapeutic agent for cancer | |
GR1006552B (en) | Endoprostatic srping (stent) impregnated with rapamycin/sirolimus and shiga toxin acting against cancer of prostate and benign hyperplasias of the urologic tract | |
EP4233536A3 (en) | Method for enhancing tumor growth | |
Hammond-Thelin | Cutaneous reactions related to systemic immunomodulators and targeted therapeutics | |
BRPI0716992A2 (en) | histone deacetylase inhibitors with combined activity on histone deacetylases class i and class iib in combination with proteasome inhibitors | |
HK1201773A1 (en) | Liquid activation system | |
FR2969312B1 (en) | PHOTOVOLTAIC MODULE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PG | Patent granted |